JP5788507B2 - 置換３−フェニル−１，２，４−オキサジアゾール化合物 - Google Patents
置換３−フェニル−１，２，４−オキサジアゾール化合物 Download PDFInfo
- Publication number
- JP5788507B2 JP5788507B2 JP2013520827A JP2013520827A JP5788507B2 JP 5788507 B2 JP5788507 B2 JP 5788507B2 JP 2013520827 A JP2013520827 A JP 2013520827A JP 2013520827 A JP2013520827 A JP 2013520827A JP 5788507 B2 JP5788507 B2 JP 5788507B2
- Authority
- JP
- Japan
- Prior art keywords
- oxadiazol
- benzyl
- ethyl
- acid
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Cc1cc(-c2n[o]c(CCCC(CCCC3)(C3=O)c3ccccc3)n2)cc(*)c1OC[C@](CO)O Chemical compound Cc1cc(-c2n[o]c(CCCC(CCCC3)(C3=O)c3ccccc3)n2)cc(*)c1OC[C@](CO)O 0.000 description 2
- HXZPVACUWPZMRC-DBPBRPCRSA-N C([C@@H]1C2)[C@H]1C=CC2[C@@H]1OCCCC1 Chemical compound C([C@@H]1C2)[C@H]1C=CC2[C@@H]1OCCCC1 HXZPVACUWPZMRC-DBPBRPCRSA-N 0.000 description 1
- AORFJQJCXUUQJW-VOTSOKGWSA-N CCOC(/C=C/C1(CCOCC1)c1cccc(C(F)(F)F)c1)=O Chemical compound CCOC(/C=C/C1(CCOCC1)c1cccc(C(F)(F)F)c1)=O AORFJQJCXUUQJW-VOTSOKGWSA-N 0.000 description 1
- KPCBGEYACDOUOV-JXMROGBWSA-N COC(/C=C/CC(CCCC1)(C11OCCO1)c1ccccc1)=O Chemical compound COC(/C=C/CC(CCCC1)(C11OCCO1)c1ccccc1)=O KPCBGEYACDOUOV-JXMROGBWSA-N 0.000 description 1
- CBJRQBNOPDOQHB-UHFFFAOYSA-N N#CC1(CCOCC1)c1cccc(C(F)(F)F)c1 Chemical compound N#CC1(CCOCC1)c1cccc(C(F)(F)F)c1 CBJRQBNOPDOQHB-UHFFFAOYSA-N 0.000 description 1
- XOCZVRFYLKLZAH-UHFFFAOYSA-N OC(C1CN(Cc(cc2)ccc2-c2n[o]c(CCC3(CCCCC3)c3ccccc3)n2)C1)=O Chemical compound OC(C1CN(Cc(cc2)ccc2-c2n[o]c(CCC3(CCCCC3)c3ccccc3)n2)C1)=O XOCZVRFYLKLZAH-UHFFFAOYSA-N 0.000 description 1
- USAXNBPRJFERID-UHFFFAOYSA-N OC(CNCCC(O)=O)c(cc1)ccc1-c1n[o]c(CCC2(CC2)c(cc2)ccc2Cl)n1 Chemical compound OC(CNCCC(O)=O)c(cc1)ccc1-c1n[o]c(CCC2(CC2)c(cc2)ccc2Cl)n1 USAXNBPRJFERID-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36592310P | 2010-07-20 | 2010-07-20 | |
| US61/365,923 | 2010-07-20 | ||
| PCT/US2011/044597 WO2012012477A1 (en) | 2010-07-20 | 2011-07-20 | Substituted 3-phenyl-1,2,4-oxadiazole compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531070A JP2013531070A (ja) | 2013-08-01 |
| JP2013531070A5 JP2013531070A5 (https=) | 2015-07-23 |
| JP5788507B2 true JP5788507B2 (ja) | 2015-09-30 |
Family
ID=44628993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520827A Expired - Fee Related JP5788507B2 (ja) | 2010-07-20 | 2011-07-20 | 置換３−フェニル−１，２，４−オキサジアゾール化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8822510B2 (https=) |
| EP (1) | EP2595969B1 (https=) |
| JP (1) | JP5788507B2 (https=) |
| CN (1) | CN103124727B (https=) |
| ES (1) | ES2539256T3 (https=) |
| WO (1) | WO2012012477A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2619190B1 (en) * | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| WO2012061459A1 (en) | 2010-11-03 | 2012-05-10 | Bristol-Myers Squibb Company | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases |
| EP2867230B1 (en) | 2012-07-02 | 2020-02-12 | Monsanto Technology LLC | Process for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles |
| US8859598B2 (en) * | 2012-10-04 | 2014-10-14 | Allergan, Inc. | 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators |
| US8957051B2 (en) | 2012-10-04 | 2015-02-17 | Allergan, Inc. | Bicyclic 1, 2, 4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators |
| TWI613182B (zh) | 2013-02-21 | 2018-02-01 | 必治妥美雅史谷比公司 | 雙環化合物 |
| WO2015073140A1 (en) * | 2013-11-14 | 2015-05-21 | Allergan, Inc. | 1,3,4-alkenyl oxadiazole amino acid derivatives as sphingosine-1-phosphate receptors' modulators |
| WO2015108577A1 (en) * | 2014-01-15 | 2015-07-23 | Allergan, Inc. | Diphenyl urea derivatives as formyl peptide receptor modulators |
| TWI689487B (zh) | 2014-08-20 | 2020-04-01 | 美商必治妥美雅史谷比公司 | 經取代雙環化合物 |
| DK3373931T3 (da) * | 2015-11-13 | 2022-11-28 | Oppilan Pharma Ltd | Heterocykliske forbindelser til behandling af sygdom |
| WO2019101511A1 (en) * | 2017-11-23 | 2019-05-31 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
| CN115197282B (zh) * | 2021-04-12 | 2024-10-11 | 中科催化新技术(大连)股份有限公司 | 一种吡喃糖苷衍生物的制备方法 |
| CN115197186B (zh) * | 2021-04-12 | 2024-04-16 | 中科催化新技术(大连)股份有限公司 | 一种生物质基吡喃糖苷衍生物的制备方法 |
| CN116375671A (zh) * | 2021-12-24 | 2023-07-04 | 晶美晟光电材料（南京）有限公司 | 一种包含四氢吡喃结构的液晶化合物的制备方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| JPS6480026A (en) | 1987-09-21 | 1989-03-24 | Mitsubishi Electric Corp | Resist coater |
| US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
| ATE448193T1 (de) | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
| US7479504B2 (en) | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
| US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| US7309721B2 (en) | 2002-03-01 | 2007-12-18 | Merck + Co., Inc. | Aminoalkylphosphonates and related compounds as Edg receptor agonists |
| JP2005533058A (ja) * | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| BRPI0410439A (pt) | 2003-05-19 | 2006-06-06 | Irm Llc | compostos e composições imunossupressoras |
| US7605171B2 (en) | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| CN1950349A (zh) | 2004-05-04 | 2007-04-18 | 默克公司 | 作为用于治疗或预防糖尿病的二肽基肽酶－ⅳ抑制剂的1,2,4－噁二唑衍生物 |
| AU2005299851B2 (en) | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| AU2006214314B2 (en) | 2005-02-14 | 2012-02-09 | University Of Virginia Patent Foundation | Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups |
| BRPI0609668A2 (pt) | 2005-03-23 | 2011-10-18 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| CN101203512A (zh) | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| WO2007024922A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| JP2009530389A (ja) * | 2006-03-21 | 2009-08-27 | エピックス デラウェア， インコーポレイテッド | Ｓ１ｐ受容体調節化合物及びその使用 |
| MX2008012738A (es) | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| TWI392671B (zh) | 2006-09-07 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 吡啶-４-基衍生物 |
| TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| ES2400163T3 (es) | 2006-09-08 | 2013-04-08 | Actelion Pharmaceuticals Ltd. | Derivados de piridil-3-ilo como agentes de inmunomodulación |
| MX2009002915A (es) | 2006-09-21 | 2009-03-31 | Actelion Pharmaceuticals Ltd | Derivados de fenilo y su uso como inmunomoduladores. |
| SG177221A1 (en) * | 2006-12-15 | 2012-01-30 | Abbott Lab | Novel oxadiazole compounds |
| US8217027B2 (en) | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
| PT2125797E (pt) | 2007-03-16 | 2014-03-11 | Actelion Pharmaceuticals Ltd | Derivados aminopiridina como agonistas do receptor s1p1/edg1 |
| EP2014653A1 (en) | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| ES2622423T3 (es) | 2007-10-04 | 2017-07-06 | Merck Serono S.A. | Derivados de oxadiazol |
| RU2010121969A (ru) | 2007-11-01 | 2011-12-10 | Актелион Фармасьютиклз Лтд (Ch) | Новые производные пиримидина |
| US20110275673A1 (en) * | 2008-09-19 | 2011-11-10 | Yibin Xiang | Inhibitors of sphingosine kinase 1 |
| US20100160369A1 (en) * | 2008-12-04 | 2010-06-24 | Exelixis, Inc. | S1P1 Agonists and Methods of Making And Using |
| EP2202232A1 (en) * | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| EP2389377B1 (en) | 2009-01-23 | 2014-07-16 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| ES2405054T3 (es) | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| JP5728487B2 (ja) | 2009-10-29 | 2015-06-03 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 三環式ヘテロ環化合物 |
| WO2011133734A1 (en) | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| EP2619190B1 (en) | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| WO2012061459A1 (en) | 2010-11-03 | 2012-05-10 | Bristol-Myers Squibb Company | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases |
-
2011
- 2011-07-20 JP JP2013520827A patent/JP5788507B2/ja not_active Expired - Fee Related
- 2011-07-20 ES ES11736263.2T patent/ES2539256T3/es active Active
- 2011-07-20 WO PCT/US2011/044597 patent/WO2012012477A1/en not_active Ceased
- 2011-07-20 EP EP20110736263 patent/EP2595969B1/en not_active Not-in-force
- 2011-07-20 US US13/811,032 patent/US8822510B2/en active Active
- 2011-07-20 CN CN201180045224.9A patent/CN103124727B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103124727A (zh) | 2013-05-29 |
| US8822510B2 (en) | 2014-09-02 |
| US20130158001A1 (en) | 2013-06-20 |
| JP2013531070A (ja) | 2013-08-01 |
| WO2012012477A1 (en) | 2012-01-26 |
| CN103124727B (zh) | 2015-03-25 |
| EP2595969A1 (en) | 2013-05-29 |
| EP2595969B1 (en) | 2015-04-22 |
| ES2539256T3 (es) | 2015-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5788507B2 (ja) | 置換３−フェニル−１，２，４−オキサジアゾール化合物 | |
| EP2382212B1 (en) | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases | |
| US9216972B2 (en) | Tricyclic heterocyclic compounds | |
| US8389509B2 (en) | Substituted pyrazole compounds | |
| JP5869579B2 (ja) | 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用 | |
| EP2635573B1 (en) | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases | |
| EP2250165B1 (en) | Triazole oxadiazoles derivatives | |
| ES2533095T3 (es) | Agonistas de receptores de esfingosina-1-fosfato | |
| JP2012515788A (ja) | 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 | |
| US20190031599A1 (en) | Indane derivatives as mglur7 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140707 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140707 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150416 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150421 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150601 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150707 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150729 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5788507 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |